Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Consistent long-term performance driving confidence for the future
Consistent strong performance
Sales
USD bn, % CAGR CC
+6%
22.3
22.9
23.6
25.4
Core Oplnc
USD bn, % CAGR CC
+13%
6.2
6.9
7.8
8.3
Innovative Medicines
Core margin (%), growth cc bps
+320bps
34.4
+280bps
36.5
+40bps
36.8
31.8
H1 2018
H1 2019
H1 2020
H1 2021
Confident on growth outlook
External expectations based on analyst consensus, as presented at
November 2020 Meet Novartis Management1 (USD bn)
47
+4% CAGR
60
60
2019 ACT
Growth
Drivers
Launches Other/Pipeline Sandoz Gx Brands
2025
Consensus
IM margin
33.5%
37.6%
All growth % in cc. IM - Innovative Medicines division. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates
refer to same period in PY. 1. Source: Novartis Investor Relations in-house consensus as of November 12, 2020.
5 Investor Relations | Q2 2021 Results
ā NOVARTIS | Reimagining MedicineView entire presentation